{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-085705","form_type":"8-K","ticker":"CARM","cik":"0001485003","company_name":"Carisma Therapeutics Inc.","filed_at":"2025-08-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.090444+00:00","generated_at":"2026-05-17T09:11:50.254437+00:00","sec_items":["1.01","3.02","5.01","5.02","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Carisma enters $5M subscription deal with Ocugen; Nasdaq deadline extended to Oct 21","bullets":["Subscription agreement with Ocugen for $5M private placement as part of concurrent $25M financing.","CEO Steven Kelly amended employment agreement with retention/transaction bonuses contingent on merger closing.","Nasdaq extends bid price compliance deadline to Oct 21; must complete merger by Oct 7 and show $4 bid price.","Merger with OrthoCellix must close by Oct 7 for continued listing on Nasdaq Capital Market."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-085705","json":"https://secwatch.observer/filing/0001104659-25-085705.json","markdown":"https://secwatch.observer/filing/0001104659-25-085705.md","text":"https://secwatch.observer/filing/0001104659-25-085705.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1485003/000110465925085705/0001104659-25-085705-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1485003/000110465925085705/tm2524685d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T09:11:50.254437+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}